Reagents and instruments for immunology, cell biology and molecular biology.
 

Abbexa

 

Abbexa is a dedicated worldwide supplier of biological tools for the life science, pharmaceutical and biotechnology research and development sectors. Abbexa provides the scientific community with primary antibodies, secondary antibodies, proteins, ELISA kits and enzymes as well as other kits and tools designed for use in research. Abbexa also offers custom protein, peptide and antibody production services to meet customer requirements.

Abbexa is committed to providing scientists and researchers with the best customer experience and high-quality products.

Abbexa’s mission is to offer unrivalled expertise and outstanding quality laboratory consumable products, striving to consistently improve. Please do get in touch with any comments regarding the website, service, products, or anything else.

 

Learn more :

 

 

  

  

 

 

         

   

  

Antibodies for Cancer Research

     

Cell Biology Antibodies

    

ELISA Kits for Accurate Detection

   Primary Antibodies
             

 

 

Website : www.abbexa.com
 
 
> Abbexa > Products for research > COVID-19 > SARS-CoV-2 - Therapeutic Candidates for Research and Development > SARS-CoV-2 - Tocilizumab - Therapeutic Candidates
SARS-CoV-2 - Tocilizumab - Therapeutic Candidates

SARS-CoV-2 - Tocilizumab - Therapeutic Candidates


Tocilizumab is a humanized monoclonal antibody that blocks the action of interleukin-6 (IL-6) receptors. The IL-6 receptor has two forms: the membrane form mIL6R and the soluble form sIL-6R. Tocilizumab can bind specifically to sIL-6R and mIL-6R and inhibit the transduction signal. It is commonly used in rheumatoid arthritis as it is immunosuppressive.
Since the beginning of the COVID-19 pandemic, it has been shown that in patients severely affected by COVID-19 caused by the SARS-CoV-2 virus, there was a "cytokine storm" that would be a major cause of mortality as the inflammatory overreaction would destroy tissues.
IL-6 is thought to be one of the mediators of the inflammation that follows the immune response against SARS-CoV-2 in the pulmonary alveoli and thus one of the cytokines responsible for this "cytokine storm" phenomenon.  Tocilizumab may therefore be a good candidate for treatment of COVID-19.

Search result : 1 product found

Refine your search :

RUOCE / IVD
  • ELISA/ELISPOT 1
  • ELISA 1
APPLY FILTERS
REINITIALIZE


Cat#
Description
Cond.
Price Bef. VAT
abx395053-96tests
Tocilizumab ELISA Kit
 96tests 
    ‹
    ›